Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017
Read more -
GSK updates on UK manufacturing network
GSK today set out several announcements made by the company to improve the efficiency and competitiveness of its manufacturing network.
Read more -
GSK announces US regulatory submission for mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a supplemental Biologics License Application (sBLA) to the United States Food and Drug Administration (FDA)...
Read more -
GSK starts phase III study with mepolizumab in patients with nasal polyps
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a phase III study with mepolizumab, an interleukin 5 (IL-5) antagonist, in patients with severe bilateral nasal ...
Read more -
GSK receives CHMP positive opinion for Synflorix pneumococcal vaccine four-dose vial
New presentation designed to significantly reduce storage requirements in developing countries.
Read more -
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC’s Advisory Meeting
Study conducted in individuals who had previously received current standard of care
Read more -
GSK announces results from 10-year continuation study showing sustained disease control with Benlysta (belimumab) in SLE
GSK today announced results from a 10-year continuation study, which showed that Benlysta (belimumab) plus standard of care prolonged control of disease activity in patients wit...
Read more -
GSK and MMV announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with Plasmodium vivax malaria
GSK and Medicines for Malaria Venture (MMV) today announced positive results from two phase III studies of tafenoquine, an investigational 8-aminoquinoline, for the prevention o...
Read more -
Four innovations to tackle under-five deaths win US$1 million Healthcare Innovation Award from GSK and Save the Children
Organisations in Pakistan, Colombia, India and Nigeria recognised for innovations helping the hardest-to-reach children Healthcare Innovation Award (HIA) is a major initiative w...
Read more -
ViiV Healthcare
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
Read more -
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
Read more -
GSK presents data at ATS on treatment effect of Nucala (mepolizumab) in severe asthma according to blood eosinophil level
GlaxoSmithKline plc (LSE/NYSE:GSK) today presented data from a post-hoc analysis of the phase IIIb MUSCA study in which first-in-class biologic Nucala (mepolizumab) consistently...
Read more -
GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA)
GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Read more -
GSK announces headline phase III results of mepolizumab in patients with severe chronic obstructive pulmonary disease
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced preliminary results of two pivotal phase III studies evaluating the efficacy and safety of mepolizumab, an IL-5 antagonist mon...
Read more -
Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care
Primary endpoint showed patients initiated with Relvar Ellipta had twice the odds of achieving an improvement in asthma control compared with patients continuing usual care.
Read more -
GSK delivers another quarter of continued progress
GSK delivers another quarter of continued progress Q1 sales of £7.4 billion, +19% AER, + 5% CER Total EPS of 21.4p >100% AER, >100% CER; Adjusted EPS of 25.0p, +31% AER, +9% CER
Read more -
GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles
Follows regulatory submissions in US, EU and Canada
Read more -
Togo becomes first country in Africa to validate the elimination of lymphatic filariasis as a public health problem
LF, commonly known as elephantiasis, is a debilitating disease caused by a parasite transmitted to humans through the bites of mosquitoes.
Read more -
GSK makes change to financial reporting framework
GSK keeps its financial reporting framework under regular review to ensure that it remains current and in line with both the latest regulatory requirements and developing best p...
Read more -
GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
